> It signals to drug companies that they can pick any terminal illness, develop a drug for it, show minimal efficacy, and get quick approval even if the side ef

> It signals to drug companies that they can pick any terminal illness, develop a drug for it, show minimal efficacy, and get quick approval even if the side effects are deadly. In the end they profit. The FDA has already put into place an accelerated approval process for this explicit purpose. The alternative is that rare diseases are too expensive/time-consuming to develop cures for, and drug companies exclusively focus on popular/easy-to-treat illnesses (more so than today). Neither world is great, but at least we get a better variety of drugs in this world. Open to better ideas still.